Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:08 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 33,183 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo, Clear all

Conditions: Basal Cell Carcinoma, Basal Cell Nevus Syndrome
Interventions: Dietary Vitamin D3 pre-treatment, Photodynamic therapy, Serum Maintenance Vitamin D3; Drug · Radiation
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: Not listed
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 2
States / cities: Phoenix, Arizona • Cleveland, Ohio

Conditions: Cutaneous T Cell Lymphoma
Interventions: Placebo, CD11301 0.03%, CD11301 0.06%; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 11
States / cities: Orange, California • Palo Alto, California • Farmington, Connecticut + 7 more

Conditions: Cystic Fibrosis
Interventions: VX-828, Placebo, Itraconazole, Midazolam, Tezacaftor, VX-118, Deutivacaftor; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 12
States / cities: Hollywood, Florida • Orlando, Florida • Overland Park, Kansas + 9 more

Conditions: Influenza
Interventions: favipiravir, Placebo; Drug
Lead sponsor: MDVI, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 860 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 60
States / cities: Birmingham, Alabama • Hunstville, Alabama • Hot Springs, Arkansas + 48 more

Conditions: Scleral Contact Lenses
Interventions: Ringers Solution, Placebo - Concentrate; Drug
Lead sponsor: University of Houston; Other
Eligibility: 18 Years to 85 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV Infections
Interventions: env (A,B,C,A/E)/gag (C) DNA Vaccine, gp120 (A,B,C,A/E) Protein Vaccine, GLA-SE adjuvant, Placebo; Biological
Lead sponsor: Worcester HIV Vaccine; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Perimenopause-Related Depression
Interventions: Estradiol, ER Beta Agonist, Placebo, Provera; Drug · Other
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 45 Years to 65 Years · Female only
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Back Pain, Low
Interventions: Naproxen, Duloxetine; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years to 64 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Otitis Media
Interventions: Cranial osteopathic manipulative treatment., Echinacea purpurea, Sham osteopathic manipulative treatment, "Echinacea purpurea" placebo; Procedure · Dietary Supplement
Lead sponsor: University of Arizona; Other
Eligibility: 12 Months to 60 Months
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2002
U.S. locations: 3
States / cities: Tucson, Arizona

Conditions: Diabetic Foot Ulcers
Interventions: Antimicrobial Peptide PL-5 Topical Spray and Placebo; Drug
Lead sponsor: Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Vista, California • Miami, Florida • Tampa, Florida

Conditions: Warm Autoimmune Hemolytic Anemia (wAIHA)
Interventions: parsaclisinib, placebo; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 10
States / cities: Los Angeles, California • Whittier, California • Miami, Florida + 6 more

Conditions: Dermatitis Atopic
Interventions: Amlitelimab, Placebo, Topical corticosteroids, Topical calcineurin inhibitors; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years and older
Enrollment: 643 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 40
States / cities: Birmingham, Alabama • Fort Smith, Arkansas • Encino, California + 32 more

Conditions: Hot Flashes
Interventions: Gabapentin; Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Metabolic Syndrome X, Overweight, Hypertension, Dyslipidemias, Prediabetic State
Interventions: Placebo Comparator: First Intervention (3 weeks), Active Comparator: Second Intervention (3 weeks), Active Comparator: Third Intervention (3 weeks), Active Comparator: Fourth Intervention (3 weeks); Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 60 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: SARS CoV-2
Interventions: Human Amniotic Fluid; Biological
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Prostate Cancer
Interventions: Vitamin E; Drug
Lead sponsor: New Mexico Cancer Research Alliance; Other
Eligibility: 18 Years and older · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Cancer Cachexia
Interventions: RC-1291 HCl, Placebo; Drug
Lead sponsor: Helsinn Therapeutics (U.S.), Inc; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 19
States / cities: Glendale, Arizona • Bakersfield, California • Encinitas, California + 13 more

Conditions: Tyrosol, Creatine, Endurance Performance, Cognition, Mood
Interventions: Tyrosol, Creatine Monohydrate, Resistant Dextrin; Dietary Supplement
Lead sponsor: Applied Science & Performance Institute; Industry
Eligibility: 20 Years to 55 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: HIV Infections, Fatigue
Interventions: Modafinil, Placebo; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Hyperparathyroidism
Interventions: Alendronate 70mg weekly; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Depression
Interventions: Infliximab, Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Long-COVID
Interventions: Mitoquinone, Placebo; Dietary Supplement
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Obsessive-Compulsive Disorder, Tricholemmoma, Skin-Picking
Interventions: Computerized cognitive training, Computerized placebo training; Behavioral
Lead sponsor: University of Wisconsin, Milwaukee; Other
Eligibility: 18 Years to 60 Years
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Acne
Interventions: TVB-3567, Placebo; Drug
Lead sponsor: Sagimet Biosciences Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 152 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Tempe, Arizona

Search by objective public record fields.

Vitamin D as a Nutritional Neoadjuvant During Photodynamic Therapy of Basal Cell Carcinoma

A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL)

Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis

Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults - T705US316

Effect of Ocular Hygiene on Scleral Lens Wear

Evaluating the Safety and Immunogenicity of Polyvalent DNA/gp120 HIV Vaccine in Healthy, HIV-uninfected Adults

Estrogen Receptor Beta and Mood

Duloxetine for LBP

Echinacea Purpurea and Osteopathy in Children With Recurrent Otitis Media

Phase II Study to Evaluate Efficacy and Safety of AMP Peptide PL-5 in Mild Infections of Diabetic Foot Ulcers

Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic Anemia

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids

Acupuncture and Gabapentin for Hot Flashes Among Breast Cancer Survivors

Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS)

Safety and Feasibility of Amniotic Fluid as a Treatment for COVID-19 Patients

Biomarker Study of Neoadjuvant Vitamin E in Patients With Locally Treatable Prostate Cancer

Placebo Controlled, Randomized Safety and Efficacy Study of RC-1291 in Cancer Anorexia/Cachexia.

The Effects of Tyrosol and Creatine on Exercise Performance and Cognition in Healthy Adults

Effectiveness of Modafinil for Treating Fatigue in Adults With HIV/AIDS

The Effects of Alendronate After Cure of Primary Hyperparathyroidism

Inflammation-Induced CNS Glutamate Changes in Depression

Long-term COVID and Rehabilitation

Neural Mechanisms of Response Inhibition Training for OCRD

Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in Healthy Participants With or Without Acne